Tanzeum (albiglutide) / GSK - LARVOL DELTA

GLP-1 Agonist Use and Outcomes in Connective Tissue Disease-Associated Interstitial Lung Disease (ACR Convergence 2026) - "Patients were categorized as GLP-1 RA users (including semaglutide, dulaglutide, liraglutide, albiglutide, exenatide, lixisenatide) or non-users, and outcomes were evaluated over a 5-year follow-up. In this large propensity score-matched cohort of patients with CTD-ILD, GLP-1 RA use was associated with a significantly reduced risk of mortality. These findings suggest a potential protective role of GLP-1-based therapies and support prospective studies to further define their role in risk modification and disease outcomes in CTD-ILD."

Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Genetic Disorders • Heart Failure • Inflammatory Arthritis • Interstitial Lung Disease • Metabolic Disorders • Myocardial Infarction • Myositis • Obesity • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • Type 2 Diabetes Mellitus

Concurrent Thiazolidinediones and GLP-1 Receptor Agonists Therapy in MASH Cirrhosis Patients: A Propensity-Score-Matched Retrospective Cohort Study (ACG 2026) - "Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis carries a significant clinical burden with unmet therapeutic needs... Our retrospective cohort study utilized the TriNetX US Collaborative Network to identify patients with MASH-related cirrhosis (ICD-10: K75.81/K76.0 plus K74.6/K74.69) receiving GLP-1RA/GIP (semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, or albiglutide) alone or with TZD (pioglitazone or rosiglitazone)... After matching, cohorts were well balanced (mean age 58.5 years; 81% White; 78% T2DM; 10% esophageal varices) except for higher BMI and HbA1c in combination cohort, reflecting TZD use as add-on therapy for refractory hyperglycemia. The combination group demonstrated a 37% relative reduction in all-cause mortality (3.7% vs. 5.1%; risk difference â1.4%, 95% CI â2.4% to â0.4%; p=0.007; HR 0.63, 95% CI 0.50â0.80; log-rank p0.001)."

Retrospective data • CNS Disorders • Diabetes • Fibrosis • Gastroenterology • Hematological Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus

Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk. (PubMed, Regul Toxicol Pharmacol) - "Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are an established treatment for management of type 2 diabetes mellitus (T2DM) and obesity...This manuscript applies that framework across seven approved GLP-1RAs: lixisenatide, exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide, and albiglutide, to evaluate the relevance of rodent thyroid tumors and the utility of 2-year bioassays for this drug class. Across all six WoE domains, the evidence supports concluding that GLP1-RAs are tumorigenic in rats via a known human-irrelevant mechanism. Thus, within the S1B(R1) WoE framework, future carcinogenicity testing in rats is unlikely to provide additional value for regulatory decision-making for this class of pharmaceuticals."

Journal • Cerebral Hemorrhage • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • Type 2 Diabetes Mellitus

Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults. (PubMed, Laryngoscope) - "GLP-1RA/GIP use in adults is linked to higher rates of laryngeal symptoms, most notably cough and voice and resonance disorders. While absolute risk differences were small, the large number of affected individuals underscores the potential clinical and public health relevance of these findings, in the context of the rapidly growing prevalence of GLP-1RA/GIP use."

Journal • Cough • Genetic Disorders • Head and Neck Cancer • Immunology • Obesity • Oncology • Respiratory Diseases • Solid Tumor

Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis. (PubMed, Endocrine) - "Periconceptional or first-trimester exposure to GLP-1 RAs are not significantly associated with HDP risk. This available evidence is limited and indicating the need for large prospective studies to establish a possible association between GLP-1 RAs are not significantly associated with HDP risk."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Diabetes • Genetic Disorders • Gynecology • Hypertension • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis. (PubMed, Diabetes Obes Metab) - "SGLT2 inhibitors consistently reduced HHF risk across the HF and T2DM networks and selected agents showed mortality benefits in clinically relevant populations. Empagliflozin showed an exploratory signal for lower VA risk in the T2DM network; however, this finding requires confirmation in trials with prespecified and adjudicated arrhythmia endpoints. Safety signals, including DKA and fracture, should be interpreted cautiously because adverse-event ascertainment was not uniform across trials."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypoglycemia • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Type 2 Diabetes Mellitus

Contractile effects of albiglutide in the human and mouse atrium. (PubMed, Front Endocrinol (Lausanne)) - "Conversely, the effect was not reversed by 10 µM propranolol, a β-adrenoceptor antagonist, and was less effective than the effect of 1 µM isoprenaline...Contractile force in abligutide-treated (100 nM) HAP in the presence of cilostamide was further enhanced by 100 nM GLP-1(7-36)amide or 10 nM exenatide but was not affected by 100 nM GLP-1(1-36)amide...In HAP, the positive inotropic effects of albiglutide-both alone and in the presence of 100 nM cilostamide-were attenuated by treatment with 100 nM exendin(9-39), a GLP-1R antagonist...Albiglutide acts as a partial GLP-1R agonist in HAP. This indicates that any clinical side effects of albiglutide may be less pronounced than those of full GLP-1R agonists."

Journal • Preclinical • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis. (PubMed, BMC Ophthalmol) - "This meta-analysis suggests that GLP-1RA therapy is not significantly associated with an increased risk of DR progression. However, heterogeneity in outcomes, particularly with semaglutide, warrants further investigation."

Journal • Retrospective data • Review • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders

The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis. (PubMed, Diabetes Obes Metab) - "GLP-1-based therapies were associated with an overall favourable cardiovascular profile in T2DM. Pairwise analyses supported class-level benefit, whereas between-agent differences were more evident for MACE than for mortality outcomes in the NMA."

Journal • Retrospective data • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study. (PubMed, Dermatol Surg) - "GLP receptor agonists were associated with a significantly reduced risk of postoperative inflammatory complications after dermatologic surgery, supporting their perioperative safety and potential beneficial role in wound healing."

Journal • Retrospective data • Genetic Disorders • Infectious Disease • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor

Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery. (PubMed, Crohns Colitis 360) - "The cohort was divided into two groups: patients with obesity and IBD prescribed GLP-1 RAs (dulaglutide, semaglutide, liraglutide, lixisenatide, exenatide, albiglutide, or tirzepatide) who had not undergone BS, and patients with obesity and IBD who underwent BS but had not received GLP-1 RAs...Despite a higher burden of comorbidities and a greater mean BMI, patients with obesity and IBD treated with GLP-1 RAs experienced significantly fewer gastrointestinal complications, thromboembolic events, disease flares, and surgical interventions compared with those undergoing BS. These findings suggest that GLP-1 RAs may represent a viable, less invasive therapeutic option for weight management and disease modulation in patients with obesity and IBD."

Journal • Addiction (Opioid and Alcohol) • Cardiovascular • Chronic Kidney Disease • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Nicotine Addiction • Obesity • Pain • Pulmonary Embolism • Renal Disease • Respiratory Diseases

CER-4-T2D: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (clinicaltrials.gov) - P=N/A | N=781430 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Jul 2026 ➔ Sep 2027 | Trial primary completion date: Jan 2026 ➔ May 2026

HEOR • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

REAL-WORLD SAFETY TRENDS OF GLP-1 RECEPTOR AGONISTS IN THE UNITED STATES: ANALYSIS OF FAERS REPORTS (2015-2025) (ISPOR 2026) - "OBJECTIVES: To descriptively characterize real world adverse event reporting associated with GLP 1 receptor agonists in the United States using FAERS data from 2015 to 2025, with a focus on patient demographics, reporter type, indications, clinical outcomes, and frequently reported reaction categories across individual GLP 1 agents. U.S. FAERS cases were extracted for albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide...Type 2 diabetes was the most frequently reported indication (77,981), followed by obesity (3,933)... GLP-1 agents show increasing real-world AE reporting in the United States, particularly for semaglutide and tirzepatide. Most reports originated from consumers, occurred among adults, and were more frequent in women."

Clinical • Real-world • Real-world evidence • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Adverse Event Reports for Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents (PAS 2026) - "Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become an increasingly utilized treatment option for pediatric obesity and type 2 diabetes...The GLP-1 RAs included in the database search were exenatide, liraglutide, semaglutide, dulaglutide, lixisenatide, albiglutide, and tirzepatide, along with their respective brand names and recombinant forms... A total of 204 adverse event reports met study inclusion criteria with a steady upward trend in number of reports each year (Figure 1). The majority of individuals had ages ranging from 15-17 years (n=79, 38.7%), 18 years (n=52, 25.5%), or '5 or less' (n=41, 20.1%). Most reports were from consumers (n=129, 63.2%) and included semaglutide (n=83, 40.7%) or tirzepatide (n=42, 20.6%)."

Adverse events • Clinical • Diabetes • Genetic Disorders • Obesity • Type 2 Diabetes Mellitus

Preferred GLP-1 Receptor Agonists in Type 2 Diabetes With Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-Analysis of Randomized Trials. (PubMed, Can J Diabetes) - "Several GLP-1-based therapies reduced MACE versus placebo, with 3-point MACE emerging as the most consistent efficacy signal. Overall, these findings support guideline-based use of GLP-1 RAs in high-risk T2DM while highlighting the need for individualized treatment selection."

Journal • Retrospective data • Review • Cardiovascular • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

Drug-specific Effects of GLP-1 Receptor Agonists on Dementia Risk: A Network Meta-analysis (AAN 2026) - "Other agents showed non-significant trends: albiglutide 30–50 mg weekly (OR 0.14; 95% CI 0.0074–2.77), efpeglenatide 2–6 mg weekly (OR 0.07; 95% CI 0.0031–1.39), lixisenatide 20 mcg daily (OR 0.33; 95% CI 0.014–8.18), semaglutide 0.5–1 mg weekly (OR 0.60; 95% CI 0.14–2.51), semaglutide 14 mg daily (OR 0.20; 95% CI 0.010–4.17), semaglutide 2.4 mg weekly (OR 0.75; 95% CI 0.17–3.35), dulaglutide 1.5 mg weekly (OR 0.78; 95% CI 0.29–2.09), and exenatide 2 mg weekly (OR 1.01; 95% CI 0.14–7.14). Conclusions Liraglutide is associated with a significant reduction in all-cause dementia, while other GLP-1 receptor agonists showed non-significant trends. These findings highlight the importance of drug-level analyses and warrant further research into cognitive effects across agents."

Retrospective data • Alzheimer's Disease • CNS Disorders • Dementia

Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus. (PubMed, J Am Coll Cardiol) - "In this large-scale real-world study, individual GLP-1RAs and SGLT2Is exhibited largely comparable cardiovascular benefits, including in patients with established CVD. These findings align with network meta-analytic estimates from major cardiovascular outcome trials and broadly support current treatment guidelines. Clinical choices should be guided by relevant factors such as safety, adherence, tolerability, cost, and patient preference, where further work is needed."

Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists and Chronic Migraine: A Real-world Cohort Study of Healthcare Utilization and Preventive Escalation (AAN 2026) - "Adults with CM initiating a GLP-1RA (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or albiglutide) within 12 months of diagnosis were compared with topiramate initiators, excluding prior use of the opposite class. Cohorts were 1:1 propensity-score-matched for demographics, BMI, comorbidities, and prior preventive use (β-blockers, TCAs, SNRIs, valproate, CGRP mAbs/gepants, Botox)...Conclusions In CM, GLP-1RA initiation compared with topiramate was associated with lower acute-care utilization and less escalation to additional preventives, despite similar baseline profiles. These findings suggest a potential role of GLP-1RAs in migraine management and warrant prospective evaluation."

Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders • Metabolic Disorders • Migraine • Pain

Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs). (PubMed, Diabetes Ther) - "This study provides a comprehensive safety comparison across all seven approved GLP-1 RAs, confirming known risks and revealing drug-specific signals-such as injection-related issues and paradoxical hyperglycemia. These findings aid personalized treatment strategies and post-marketing surveillance."

Adverse events • Journal • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Pain • Pancreatitis • Type 2 Diabetes Mellitus

Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. (PubMed, Diabetes Metab Syndr Obes) - "GLP-1 RAs were associated with increased risks of diarrhea (RR 2.33, 95% CI 1.35-4.01; p = 0.002) and nausea (RR 2.94, 95% CI 1.66-5.21; p = 0.0002). These findings suggest that GLP-1 RAs confer significant cardioprotective benefits in elderly patients with T2DM, although gastrointestinal adverse effects warrant careful monitoring."

Journal • Retrospective data • Review • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Dermatologic side effects of GLP-1 receptor agonists: A Cross-sectional Analysis (AAD 2026) - "Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the management of diabetes and obesity, with gastrointestinal side effects being the most commonly reported...Search terms included: GLP-1 Receptor Agonist, Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide, Lixisenatide, Albiglutide... Dermatologic AEs due to GLP-1 RAs use are relatively uncommon. Injection-site reactions represent the most frequent cutaneous complication, while alopecia, dermatitis, and urticaria are rarely reported. Proactively anticipating and addressing these dermatologic AEs are essential to optimizing patient care and counseling."

Adverse events • Alopecia • Dermatitis • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pruritus • Urticaria

A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus. (PubMed, Diabetes Metab Syndr Obes) - "When compared with oral semaglutide, exenatide, dulaglutide, lixisenatide, and albiglutide, liraglutide showed comparable efficacy. Liraglutide 1.2 mg showed a numerically lower incidence of nausea and similar rates of vomiting compared with other GLP-1RAs. Liraglutide 1.2 mg and 1.8 mg doses improve weight and glycemic outcomes with a favourable safety profile, supporting its role as an effective therapeutic option for comprehensive management of T2DM with comorbid obesity."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

HARMONIZED META-ANALYSIS OF GLP-1 RECEPTOR AGONIST CARDIOVASCULAR OUTCOME TRIALS: CONSISTENT REDUCTION IN 3-POINT MACE (ACC 2026) - " To assess GLP-1RA effects on 3-point MACE (CV death, nonfatal MI, nonfatal stroke) and the impact of endpoint harmonization, we meta-analyzed eight placebo-controlled CV outcome trials: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide s.c.), EXSCEL (exenatide), HARMONY (albiglutide), REWIND (dulaglutide), PIONEER-6 (oral semaglutide), and AMPLITUDE-O (efpeglenatide). Across >60,000 T2D patients, GLP-1RAs reduced 3-point MACE by ~14%. By harmonizing endpoints and eliminating trial-level variation, this analysis clarified a consistent class effect, contrasting prior heterogeneous reports and reinforcing GLP-1RAs as a cornerstone of ASCVD prevention."

Retrospective data • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Preoperative GLP-1 Receptor Agonist Exposure Is Associated with Increased Risk of Repeat Flexor Tendon Sheath Tenolysis and Diagnosis in Diabetic Patients: A Propensity-Matched Cohort Study (AAOS 2026) - "Eligible agents included liragluti de, semaglutide, dulaglutide, exenatide, albiglutide, and lixisenatide...Propensity score matching (1:1) was performed based on age, sex, race, body mass index, hemoglobin A1c, hypertension, obesity, chronic kidney disease, heart failure, and concurrent metformin use... Preoperative exposure to GLP-1 receptor agonists was independently associated with increased three-year risk of both repeat flexor tendon sheath tenolysis and recurrent trigger finger diagnosis in diabetic patients. These findings contradict assumptions that GLP-1 RAs confer general anti-inflammatory benefit across tissues and suggest the need for further investigation into their effects on tendon homeostasis and fibroproliferative signaling pathways. Hand surgeons should consider GLP-1 RA exposure as a potential risk factor when counseling diabetic patients undergoing tenolysis."

Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypertension • Inflammation • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis. (PubMed, Diabetes Metab Res Rev) - "GLP-1 RAs may be associated with a lower risk of colon cancer in adults with type 2 diabetes mellitus, warranting further validation in trials among high-risk populations."

Clinical • Journal • Retrospective data • Review • Colon Cancer • Colorectal Cancer • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Solid Tumor • Type 2 Diabetes Mellitus